AstraZeneca (AZN) -Oxford vaccine prevents 79% of Covid cases, US data shows.

relates to Astra vaccine with 79% effectiveness in US, shows no safety concerns

Photographer: Zoltan Mathe / AFP / Getty Images

AstraZeneca Plc’s coronavirus vaccine performed better than expected in a clinical trial in the US, providing peace of mind about its safety and efficacy.

The vaccine developed with the University of Oxford was 79% effective in preventing Covid-19, and an independent monitoring board found no safety concerns, the company he said on Monday. The vaccine also protected all those immunized from serious illness and death in a study of more than 30,000 volunteers.

The findings should reinforce confidence in the product after confusion about its true efficacy and the best dosing regimen impacted on absorption. The vaccine has faced numerous setbacks, most recently due to supply problems and possible side effects. Even after the The European Medicines Agency declared it safe last Thursday, not all European Union countries have resumed vaccination due to concerns about reports of blood clots.

“Efficiency is better than we expected,” Jefferies analyst Peter Welford wrote in a note to clients. “Importantly, after recent largely unfounded safety concerns in Europe, the study confirms the safety profile.”

Read more: EU regulator considers Astra safe, but recommends a warning label

Astra shares rose as much as 1.2% in London trading.

A deficit in deliveries to the EU has put Astra disagrees with the bloc and led officials to oppose the region’s exports of the injection as they seek to hold the company to account.

Read more: Vaccine battle escalates with EU ready to stop UK shipments


Source link